Navigation Links
YSR launches 'Operation Dengue'

'Operation Dengue', State's war against mosquitoes has been formally launched by the Chief Minister Y. S. Rajasekhara Reddy on Friday formally from the Jali Hanuman temple area of Pardiwada in Maharajgunj constituency here. //

The operation will also include an added impetus on the phasing out of the dustbin system of garbage collection in Hyderabad with each household being supplied with small plastic bins. Garbage collectors on cycle rickshaws will collect these bins. Dr Reddy said that its aim was to make Hyderabad a dustbin-free city by December this year.

Dr. Reddy has stated that `Operation Dengue' would be a sustained movement for three years and has called upon the public to aid the Government in the complete eradication of mosquitoes that are responsible for diseases such as dengue, chikungunya and malaria.

Around 3,000 cycle rickshaws have been employed to undertake this job in the twin cities in order to collect garbage directly from households while 300 teams have been assigned designated areas for anti-malarial operations. Each team would visit 200 households.

He said, "You will have to cooperate with them and make sure that both the interiors and exteriors of your house are made safe from mosquitoes."

Yesterday while administering an anti-mosquito/dengue pledge to Government officials, a few school students and public at the Dhoolpet stadium, the Chief Minister said the Government was not leaving any stone unturned in its efforts to curb the mosquito menace.

Dr Reddy said that unlike chikungunya dengue fever was fatal. He pointed out that while dengue had first reared its head in North India before spreading to the South. chikungunya had followed the opposite path.

He said, ‘Dengue fevers are normal in September, October and November every year. But this year, it has been more prevalent and we have to be careful.’ He added, ‘You should make sure that there is no water stagnation anywh
'"/>




Page: 1 2

Related medicine news :

1. Glaxo launches pills to help smokers quit in 7-12 weeks
2. Dr Reddy’s Laboratories launches Hyalosy
3. GlaxoSmithKline launches diabetes and cancer drugs
4. Cipla launches 3-in-1 AIDS drug in India
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: YSR launches Operation Dengue

Breaking Medicine News(10 mins):Health News:MassMutual Recognized as One of America's Healthiest Companies 2Health News:MassMutual Recognized as One of America's Healthiest Companies 3Health News:New research identifies modifiable risk factors for heart disease 2Health News:New research identifies modifiable risk factors for heart disease 3Health News:New research identifies modifiable risk factors for heart disease 4Health News:New research identifies modifiable risk factors for heart disease 5Health News:New research identifies modifiable risk factors for heart disease 6Health News:Magnetic field measurements of the human heart at room temperature 2Health News:Magnetic field measurements of the human heart at room temperature 3Health News:National Oncologist Group Warns: Current Health Care Reform Legislation Woefully Short In Addressing Cancer Care Crisis 2Health News:National Oncologist Group Warns: Current Health Care Reform Legislation Woefully Short In Addressing Cancer Care Crisis 3Health News:National Oncologist Group Warns: Current Health Care Reform Legislation Woefully Short In Addressing Cancer Care Crisis 4Health News:Spice Compounds May Stem Tumor Growth 2
Breaking Medicine Technology:Within3 Expands into Mobile Applications 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program 2RecoverCare and MedaSTAT USA Complete Transaction 53601 1RecoverCare and MedaSTAT USA Complete Transaction 53601 2RecoverCare and MedaSTAT USA Complete Transaction 53601 3BMP Sunstone Divests Ownership Stake in Alliance BMP Limited 53599 1BMP Sunstone Divests Ownership Stake in Alliance BMP Limited 53599 2AlphaRx and Venturepharm Announce Collaboration Agreement 53597 1AlphaRx and Venturepharm Announce Collaboration Agreement 53597 2